Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**18F-FHBG** is a fluorine-18-labeled acycloguanosine derivative used as a positron emission tomography (PET) imaging agent. It acts as a specific substrate for herpes simplex virus type 1 thymidine kinase (HSV1-tk), which phosphorylates and traps the compound in cells expressing this gene. This property enables noninvasive imaging of HSV1-tk gene expression, making it valuable for monitoring gene transfer efficiency and tracking therapeutic transgenes in vivo, particularly in the context of cancer gene therapy and cell-based therapies. The tracer demonstrates favorable pharmacokinetics, rapid blood clearance, low background signal, biosafety, and acceptable radiation dosimetry in humans[2][3][4]. It does not cross the blood-brain barrier under normal conditions[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-FHBG.